In Vivo is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

University of Massachusetts Medical School

http://www.umassmed.edu/

Latest From University of Massachusetts Medical School

In Five Years, People Will Navigate Their Health Care With An AI Advisor – Verily’s Andrew Trister

The digital “agent” on the horizon will draw on users’ entire health record, data from wearables and other sources to steer them in making health decisions. In this second part of a two-part series, Andrew Trister, chief scientific officer and chief medical officer at Verily, discusses his vision for the future and current obstacles.

Digital Health Artificial Intelligence

Tech Transfer Roundup: Tiba And CEPI Strategize Together On ‘Disease X’

Immix collaborates with Israeli research institutions on BCMA-targeted CAR-T therapy. NeoImmuneTech/NIAID alliance could pave way for “animal rule” approval in acute radiation syndrome.

Tech Transfer Round-Up Deals

Digital Health And Pharma Still Defining Rules Of Engagement

Despite all of the buzz around adoption of digital health tools and whopping VC investments in consumer-facing digital health firms, pharma has yet to articulate a business model for co-development or integration of behavior-modifying digital therapeutics into their portfolios.

Strategy Digital Health

Tech Transfer Roundup: Boehringer Teams Up With A*STAR On Targeted Oncology R&D

National Resilience, Parker Institute team to incubate cancer startups. Metropolitan AntiViral Drug Accelerator will focus on eight molecular features of SARS-CoV-2 to create novel oral antivirals.

Tech Transfer Round-Up Deals
See All

Company Information

  • Industry
  • Academic and Research Institutions
  • Other Names / Subsidiaries
    • University of Massachusetts
UsernamePublicRestriction

Register